Search Health Affairs    [advanced]
Author:
Keyword(s):
Year:  Vol:  Page: 




Blog
From The Staff

Health Affairs Briefing: Health Reform & The 2008 Election


May 5th, 2008
by Chris Fleming

What role will the issue of health care reform play in the 2008 presidential election? How would the candidates control rising health costs and cover the uninsured, and how will the economic downturn affect efforts to expand access? Would the candidates’ reform proposals fix the health system’s flaws? What lessons can be drawn from previous health care reform efforts?

Join representatives from the Clinton, Obama and McCain presidential campaigns to tackle these and other questions at a Tuesday, May 13 briefing highlighting the May/June issue of Health Affairs, which focuses on health reform. Susan Dentzer, the journal’s Editor-in-Chief, will moderate the briefing, which will take place from 8:45 AM until noon at the Willard Hotel. Leading political pollsters Celinda Lake and Bill McInturff will discuss the prospects for health reform. Congressional Budget Office Director Peter Orszag and Jason Furman of the Brookings Institution will examine the potential of different strategies, from tax credits to individual mandates, to reduce costs and improve quality and access. Read the rest of this entry »

A Cloudy Crystal Ball For Election-Year Health Politics


April 29th, 2008
by Rob Cunningham

UnitedHealth Group officials may have been laying protective cover for themselves when they attributed poor first-quarter earnings to a sagging economy last week. But that doesn’t mean it isn’t also true, as United said, that business is bad because the company’s products are getting too expensive for a growing number of workers and companies. Coming within weeks of similar announcements by WellPoint and Aetna, United’s bad news represents a conundrum for any candidate who wants to talk about expanding coverage in 2009 — and most of them do. Read the rest of this entry »

Universal Coverage’s Mixed Picture


April 16th, 2008
by Jonathan Gardner

In interviews with Health Affairs, government ministers in Germany and the Netherlands talk up market-oriented refinements to their universal health insurance systems for the future. But the news from Europe isn’t all happy: an unsettling survey in the United Kingdom finds that some physicians believe that the market will unravel the government-owned and -operated National Health Service (NHS) in the next decade.

The online poll of more than 500 general practitioners (GPs) conducted by Pulse, which describes itself as “UK’s leading medical weekly,” found that 84% believed that the NHS would not exist “as we know it” in ten years’ time and that only one-third believe that the NHS will be free at the point of use in the same amount of time. Read the rest of this entry »

Who You Gonna Call? Getting a Handle on Mental Health Care


April 9th, 2008
by Rob Cunningham

It’s been nearly five years since the President’s New Freedom Commission on Mental Health issued its final report. The report affirmed the possibility of recovery and the effectiveness of available treatments for many conditions. But it also warned that many patients never find their way to care and that providers are often unaware of therapies that have proved their worth.

The commission also marshaled evidence of the crucial importance of ancillary services like supported housing and employment and income-support programs for the severely ill. But it candidly acknowledged that management of these services is in most cases hopelessly fragmented among siloed government departments with no collaborative traditions. Read the rest of this entry »

New Atlas Features Roadmap To Medical Homes


April 7th, 2008
by Rob Cunningham

Because the most glaring geographic variations in health care use have been observed in specialty and end-of-life care, policymakers have had trouble coming to terms with the work of John Wennberg and his Dartmouth colleagues. The questions the Dartmouth researchers raise about spending and quality are too disruptive, too threatening. Specialty and end-of-life care are too sensitive for the blunt instruments of policy to address.

But with publication today of the latest edition of the Dartmouth Atlas, focused on chronic care, Wennberg and company carry their analysis to the most fundamental, everyday questions about the organization and delivery of care. The new Atlas joins the battle for health system improvement on a level that everyone can understand. It engages with questions that have immediate meaning for Congress, consumers, and many medical professionals and throws its weight behind policy proposals that already have widespread support. Wennberg is no longer a lonely voice crying out in the wilderness. Read the rest of this entry »

Susan Dentzer Named New Health Affairs Editor-In-Chief


March 28th, 2008
by Chris Fleming

Health Affairs and its publisher Project HOPE are pleased to announce that Susan Dentzer will become the journal’s new editor-in-chief on May 1, 2008.

Dentzer, one of the nation’s most respected health policy journalists, is currently an on-air correspondent for The NewsHour with Jim Lehrer on the Public Broadcasting Service. She heads The NewsHour’s health unit, which she helped create in 1998, and appears frequently on other programs such as Nightline and The McLaughlin Group. Her nearly three decades of journalistic experience span both broadcast and print media and include service as the chief economics correspondent at U.S. News & World Report and a senior business writer at Newsweek.

Dentzer has spoken on health care and other policy issues to a wide array of governmental, professional, and educational groups, and she has moderated panel discussions on key policy questions for organizations such as the AARP and the BlueCross BlueShield Association. She was selected through a process led by Health Affairs Founding Editor John Iglehart and will succeed Jamie Robinson, who is returning to his previous position as the Kaiser Permanente Distinguished Professor of Health Economics at the University of California, Berkeley, School of Public Health. Read the rest of this entry »

Foundation Angels Ascending The Ladder Of Social Determinants


March 28th, 2008
by Sarah Dine

As Jacob, one of the three Old Testament patriarchs, flees from his brother Esau, he stops for the night at Bethel, where he dreams of a ladder going from earth to heaven with the angels of God ascending and descending the ladder (Genesis 28:11-19). There is extensive biblical commentary on this dream and particularly on why the angels are first ascending and then descending.

However, as anyone who follows the research on economic mobility and social determinants of health knows, you are always better off ascending the ladder rather than descending it. The spiritual “Jacob’s Ladder” also used the imagery of the ladder to symbolize the climb out of slavery and into freedom. Read the rest of this entry »

Can This Marriage Be Saved?: MedPAC Plays Matchmaker


March 26th, 2008
by Rob Cunningham

A lot of pipe dreams have been stoked by the seductive notion of “aligning incentives” — a catchphrase of the managed care era that promised better quality and lower costs in one magical bubble. But the divergent interests of patients, payers, and providers are in reality more likely to collide than align, a circumstance that has consigned most of this well-intentioned abstraction to the recycling bin.

In recent years, this journal has documented an increasingly competitive medical marketplace. While cheered by market fundamentalists, this wave of entrepreneurial enthusiasm has problematic implications for the critical issues of fragmentation of care and perverse incentives to overtreat. The most troubling of these has been the deepening of fault lines between hospitals and physicians. Read the rest of this entry »

Getting Religion: The Revival Of SCHIP


March 21st, 2008
by Sarah Dine

The State Children’s Health Insurance Program was supposed to be the MVP of various health care policy initiatives in 2007. SCHIP reauthorization, featured widely in conferences, at meetings, and on the Health Affairs Blog, had broad, bipartisan support uniting very strange bedfellows of all political stripes. Nonetheless, two bills for reauthorization were vetoed, and a modest extension keeps the program running for another day.

The original SCHIP bill represented a triumph of bipartisanship led by Sens. Orrin Hatch (R-UT) and Ted Kennedy (D-MA) after years of dispiriting controversies over the Clinton health reforms and budget fights in Congress. Along with several other health care initiatives of the 1990s, it was a hardy offshoot from the failure of comprehensive reforms pushed by the Clinton administration in the early 1990s. Any program with that kind of support and history is tough to keep down. The congressional election in Illinois’ 14th district on March 8 bears witness to phoenix-like qualities of SCHIP.

 

Read the rest of this entry »

Holy Benchmarks, Batman! A Real Policy Debate Breaks Out


March 14th, 2008
by Rob Cunningham

Like a recurring illness, stalemate looms again over the prospects for settling the issue of payment levels to private plans in Medicare, which now exceed the average per beneficiary cost of traditional fee-for-service Medicare by 13 percent, according to the Medicare Payment Advisory Commission. MedPAC recommends eliminating the differential, which funds extra benefits for private-plan enrollees. House Ways and Means Health Subcommittee chair Pete Stark (D-CA) and most other Democrats agree.

But as always in health care, one guy’s costs are another guy’s revenues. The excess payments are catnip to the plenipotent insurance lobby. Rural Senators Max Baucus (D-MT) and Charles Grassley (R-IA) opposed sharp cuts last year from their insurmountable position atop the Senate Finance Committee, dutifully protecting the interests of constituents who benefit from the Medicare Advantage program’s largesse. Likewise, the NAACP supports the current scheme, which also subsidizes low-income minority beneficiaries. And President Bush has vowed to veto any significant reduction.

In the midst of this partisan impasse, amazingly, a disinterested policy debate broke out last week with the publication of Bob Berenson’s compromise proposal in Health Affairs [1-week free access]. In recognition of Berenson’s stature in the policy community, MedPAC chair Glenn Hackbarth paid him the compliment of a public response in a March 10 interview with CQ HealthBeat’s John Reichard.

Read the rest of this entry »

Contributing Voices

Indiana: Health Care Reform Amidst Colliding Values


May 1st, 2008
 
by Mitchell Roob and Seema Verma

In May 2007, Indiana enacted comprehensive health reform in the form of the Indiana Check-Up Plan and its centerpiece, the Healthy Indiana Plan (HIP). After intense negotiations, the Centers for Medicare and Medicaid Services granted Indiana the 1115b waiver required for the plan to go into effect in December 2007, and within three months over 30,000 Hoosiers had applied for the program.

HIP is the first Medicaid expansion in the nation to be modeled in the spirit of a high deductible health plan (HDHP)/ health savings account (HSA). This structure melds two themes of American society that typically collide in our healthcare system, rugged individualism and the Judeo Christian ethic. HIP combines these diametrically opposed themes by promoting personal responsibility while providing subsidized health protection to those who can least afford it. Read the rest of this entry »

Fantasy At FDA: Protecting The Public From Drug Company Reprints


April 23rd, 2008
by Jerome Kassirer

Editor’s Note: Should drugmakers and medical device manufacturers be allowed to provide physicians with medical and scientific journal articles concerning uses of their products that have not been approved by the Food and Drug Administration? Recently, the FDA issued draft guidance that would permit this practice with certain regulatory restraints. In the post below, Jerome Kassirer argues that the guidance would allow the distribution of potentially biased information and would discourage rigorous FDA review of new uses of drugs and devices. Scott Gottlieb, however, argues that the guidance would facilitate access to potentially life-saving information while ensuring that any research distributed is credible and transparent.

Two of the principal criteria of the Food and Drug Administration’s (FDA’s) new guidance on distribution of reprints describing off-label drug use are that the journal of origin must be peer reviewed and have a disclosure policy. The notion that peer review and disclosure will protect the public is, in my judgment, magical thinking. Anthropologist Philips Stevens Jr. says that magical thinking invests symbols with special powers and forces. Peer review and disclosure are two of these powerful symbols, and, in my opinion, both have been afforded far more credibility than they deserve. Read the rest of this entry »

From FDA, A Good Framework For Distributing Information On Off-Label Uses


April 23rd, 2008
by Scott Gottlieb

Editor’s Note: Should drugmakers and medical device manufacturers be allowed to provide physicians with medical and scientific journal articles concerning uses of their products that have not been approved by the Food and Drug Administration? Recently, the FDA issued draft guidance that would permit this practice within certain regulatory restraints. In the post below, Scott Gottlieb argues that the guidance would facilitate access to potentially life-saving information while ensuring that any research distributed is credible and transparent. Jerome Kassirer, however, argues that the guidance would allow the distribution of potentially biased information and would discourage rigorous FDA review of new uses of drugs and devices.

In early 2005, results of a large, government-run study showed that when the breast cancer drug Herceptin was used after surgery in the treatment of certain early-stage tumors, it could cut their chances of relapsing in half. It was a dramatic result. Herceptin, which was developed by Genentech, had been used for years in patients with advanced breast cancers, and with good results. But this was the first significant study to show that when the drug was used in the earlier stages of the disease, its benefits could be even more impressive.

It is rare in the practice of medicine that the introduction of a single treatment can produce such significant benefits relative to its known risks. In breast cancer, perhaps only tamoxifen (administered for five years to patients with estrogen-receptor–positive primary breast cancer) produces as significant of a reduction in the risk of cancer recurrence. The New England Journal of Medicine, in an editorial, called the studies with Herceptin “not evolutionary but revolutionary.” The results resonated around the cancer community. Read the rest of this entry »

Health IT: The Time Is Now


April 2nd, 2008
by Ivan Seidenberg

Americans need and deserve health information technology (IT). As the chairman and CEO of Verizon Communications Inc. and the only business representative on a federal commission to develop a strategy for health care IT standards, I have spent considerable time over the past several years promoting this technological necessity.  

In addition, Verizon helped found an unprecedented, broad-based coalition of health associations, consumer groups, labor unions, patient organizations, and other businesses to urge Congress to pass a health IT bill. I’m also the chairman of the Health and Retirement Task Force of the Business Roundtable, so on Wednesday (April 2) I will join Sen. Edward Kennedy (D-MA), Sen. Mike Enzi (R-WY), and Ron Williams, chairman and CEO of Aetna, to urge Congress to pass the Wired for Health Care Quality Act, authored by Senators Kennedy and Enzi. Read the rest of this entry »

The U.K Health System: A Rorschach Test For U.S. Reporting


March 31st, 2008
 
by Geraint Lewis and Richard Gleave

Editor’s Note: This post was written by several of the 2007-08 Commonwealth Fund Harkness Fellows. These fellowships allow mid-career health services researchers and practitioners from Australia, Germany, the Netherlands, New Zealand, and the United Kingdom to spend up to 12 months in the United States, conducting original research and working with leading U.S. health policy experts. The lead authors of the post are Richard Gleave and Geraint Lewis. Additional authors include Kalipso Chalkidou, Andreas Gerber, Ruth McDonald, and Rhema Vaithianathan.

A recent article in the New York Times (“Paying Patients Test British Health Care System,” 21 February 2008) demonstrated a bias in the reporting of an international health care issue. The article focused on the case of a terminally ill woman in England who was prevented from paying privately for a high-cost cancer drug (Avastin) whilst she was being treated by the National Health Service (NHS).

The article broached three separate issues: (1) access to expensive drugs and technologies; (2) cost-effectiveness evaluation of new drugs and technologies; and (3) private top-up within public health care provision [supplementing publicly provided services with private services paid for out of pocket]. Each of these topics is relevant to the health care reform debate in the United States, but the way in which the article confounded the three distorted the issues. Read the rest of this entry »

Physician Ownership And Self-Referral: A Commentary


March 27th, 2008
by Christine Cassel

Editor’s Note: This is the last in a series of posts in response to Jon Gabel’s article “Where Do I Send Thee? Does Physician-Ownership Affect Referral Patterns To Ambulatory Surgical Centers?,” published March 18 on the Health Affairs Web site. Rep. Michael Burgess (R-TX) began the series, which also featured Jerry Cromwell.

The tension between commerce and professionalism is not new. Maimonides warned against allowing “thirst for profit . . . to interfere with my profession . . . the great task of attending to the welfare of Thy creatures.”[1] In 1913, George Bernard Shaw famously opined that “the object of the medical profession today is to secure an income for the private doctor; and to this consideration all concern for science and public health must give way when the two come into conflict.” He added, somewhat reassuringly, “Fortunately, they are not always in conflict.”[2] In 1930 the American Medical Association (AMA) Judicial Council judged that the widespread practices of fee-splitting, commissions, and referral to physician owned diagnostic laboratories, which they referred to as “rake-offs,” were unethical.[3]

In the pre-Flexner era, medicine was an unregulated and largely unscientific enterprise. Physicians didn’t make much money, and dispensing of patent remedies and kickbacks for referrals were standard practice. But now, even where a more robust science base exists and where regulation has emerged as a concomitant of public concern and public responsibility for financing, there are limits to the effectiveness of regulation in dealing with these kinds of conflicts of interest. I suggest here that professional values must be a component of the solution.